Cardiovascular diseases (CVDs) constitute the prime cause of global mortality, with an
immense impact on patient quality of life and disability. Clinical evidence has revealed a …

Metformin is currently the first-line drug treatment for type 2 diabetes. Besides its glucose-
lowering effect, there is interest in actions of the drug of potential relevance to cardiovascular …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibition reduces heart failure
hospitalizations in patients with diabetes, irrespective of glycaemic control. We examined the …

Rationale: The diabetes mellitus drug metformin is under investigation in cardiovascular
disease, but the molecular mechanisms underlying possible benefits are poorly understood …

Aims Heart failure with preserved ejection fraction (HFpEF) is a multifactorial disease that
constitutes several distinct phenotypes, including a common cardiometabolic phenotype …

Heart failure (HF) is growing to a modern epidemic and despite advances in therapy, it still
carries an ominous prognosis and a significant socioeconomic burden. 1 Many novel agents …

The biguanide metformin is widely prescribed for Type II diabetes and has anti-neoplastic
activity in laboratory models. Despite evidence that inhibition of mitochondrial respiratory …

Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more
than 60 years. The United Kingdom Prospective Diabetic Study (UKPDS) has shown …

Considerable efforts have been made since the 1950s to better understand the cellular and
molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now …

Improvements in healthcare and nutrition have generated remarkable increases in life
expectancy worldwide. This is one of the greatest achievements of the modern world yet it …